No abstract

No abstract

No abstract

No abstract

Summary. A study of the fibrinolytic enzyme system in 37 cirrhotic patients at rest and 15 cirrhotic patients following a treadmill exercise procedure is reported. An outstanding feature of the resting studies was a significant elevation in the levels of plasma plasminogen activator and serum fibrin/fibrinogen degradation products, when compared to age and sex‐matched healthy controls. Moreover, there was a significant positive correlation between those two fibrinolytic parameters. No significant difference was demonstrated between the control and cirrhotic groups in relation to plasma fibrinogen, euglobulin plasminogen and plasma urokinase inhibitor activity. The exercise studies showed that following an entirely physiological stimulus the plasminogen activator response in some cirrhotics was excessive in terms of either the initial response and/or prolongation of the recovery period. However, an exaggerated initial response was not necessarily followed by a prolongation recovery period nor was a relationship established between the resting levels of plasminogen and an abnormal exercise response. Furthermore, there was no correlation between the increases in plasminogen activator and serum fibrin/ fibrinogen degradation products following exercise.

Clonidine in Treatment of Hypertension-Amery et al. BRITMIS 395 al. (1969) mentioned that a dose of 0.4 to 1.2 g. of clonidine is equivalent to 1.5 to 2.0 g. of methyldopa. These data and our present findings agree on the following points: that 0-7 mg. of clonidine corresponds to about 1 g. of methyldopa, that blood-pressure control can be achieved at least as well with clonidine as with methyldopa, and that side effects are more frequent during clonidine than during methyldopa treatment. The present study compares only clonidine-chlorthalidone to methyldopa-chlorthalidone. To specify the exact place of clonidine of prolonged treatment of hypertension a comparative study of clonidine and other antihypertensive agents is desirable. REFERENCESColwil,

of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary. A tanned cell haemagglutination technique using inactivated Au‐Ag to sensitize human ‘O’ Rh negative crythrocytes is described. The method may be used to detect Au‐Ag by haemagglutination inhibition (HI) and anti‐Au by direct haemagglutination (HA). Sensitivity and specificity arc demonstrated and its application to mass donor screening is considered.